Jaipur, India — Rajasthan’s Health Minister Gajendra Singh Khimsar faced scrutiny in the Assembly Tuesday regarding alleged fatalities linked to a cough syrup, asserting that the state government and healthcare providers were not to blame since the medication was administered without professional guidance. His comments follow a tragic incident in October 2025, which raised concerns over the safety of certain pharmaceutical products after several children reportedly died after consuming the syrup.
During the Question Hour, Khimsar addressed accusations of collusion between government officials and pharmaceutical companies involved in the cough syrup supply chain. He clarified that accountability would be assigned only if the syrup had been prescribed by a qualified doctor. “If a healthcare professional recommends a medicine and it results in fatalities, the responsibility lies with them and the government. However, in cases where families administer medications without consultation, those parties cannot be faulted,” he stated.
The health minister acknowledged the deaths were not widespread, estimating between two and five fatalities tied to the medicine. He expressed concern about misuse, alleging that some parents administered dosages intended for themselves to their children. “Cough syrups often contain ingredients such as codeine. These incidents appear to stem from overdoses rather than any defect in the medication itself,” he remarked, defending the quality of the product in question.
Khimsar’s statements sparked immediate backlash from opposition leaders, who vehemently contested his claims. Tikaram Jully, the Leader of the Opposition, accused the minister of downplaying the severity of the situation, pointing out that the cough syrup had been sourced from a manufacturer with a questionable record. “This company has faced blacklisting in multiple regions,” Jully contended, arguing that the syrup’s longstanding use does not absolve current concerns about its safety.
Further complicating the narrative, Jully highlighted Khimsar’s implication of overdose, asserting that the minister effectively acknowledged that the medication’s administration could indeed be fatal. He maintained that while the cough syrup may have initially met acceptable standards, its quality could have deteriorated over time.
The controversy surrounding this medication has provoked wider discussions about regulatory oversight and the need for strict monitoring of pharmaceutical supplies. The government faces mounting pressure to ensure that such incidents do not reoccur, prompting calls from both citizens and health advocates for improved safety protocols.
Rajasthan’s legislative assembly continues to grapple with maintaining public trust in health policies, particularly in light of such alarming situations. As the investigation unfolds, the focus remains on accountability and the critical importance of medical guidance in prescribing and administering medication.